Answers are grounded in this paper and cite their sources.
Review highlights synergistic antitumor efficacy of photothermal agents and checkpoint inhibitors in cancer models, indicating strong potential for multimodal therapy.
BACKGROUND: Immunophotothermal therapy (IPTT), combining immune checkpoint inhibitors and photothermal therapy, represents a promising synergistic anticancer strategy that enhances tumour-specific immunity alongside localised thermal ablation. AIM: This review aims to summarise and critically analyse recent advancements in the development of photothermal agents for IPTT and their synergistic applications with immune checkpoint inhibitors. METHODS: We focus specifically on the progress in innovative photothermal agent materials, the underlying mechanisms of immunophotothermal synergy, and the resulting antitumor efficacy evidenced by preclinical and clinical findings. CONCLUSIONS: Furthermore, the key challenges hindering clinical translation and potential future directions are discussed. This comprehensive analysis highlights the current state and prospects of IPTT as an effective multimodal cancer treatment paradigm.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: